Breaking News

CBC Group Acquires UCB’s Mature Neurology & Allergy Business in China

UCB’s medicine portfolio will serve as an anchor asset as CBC works to build out a leading integrated central nervous system (CNS) biopharma platform in China.

Author Image

By: Charlie Sternberg

Associate Editor

CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, has completed the strategic acquisition of global biopharmaceutical company UCB’s mature neurology and allergy business in China, in partnership with Mubadala Investment Company.   The acquisition marks another successful transaction under CBC’s buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in Ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters